Current treatments are limited and often lead to significant side effects, underscoring the need for new, well-tolerated options
Retatrutide is an investigational triple incretin receptor agonist targeting GLP-1, GIP, and glucagon receptors to reduce appetite and body weight, while tesamorelin is a growth hormone-releasing hormone analogue that stimulates pituitary GH release to reduce visceral fat, primarily in HIV-positive patients with lipodystrophy
some of it is an art. The microdosing works so effectively that she said its cutting into the plastic surgery side of her business
Kimanis client, Jessica Bunge, 37, went on Ozempic in June for diabetes
These symptoms are generally mild and transient, improving as the digestive system adapts to the medication
Amgen's 2026 real-world evidence presentations noted that GLP-1 benefits are closely tied to sustained treatment use, while many patients discontinue within the first year in routine practice